1. 106580892 一种苦柯胺B注射用组合物
CN
26.04.2017
A61K 9/19 Loading...
A61K 9/19
Loading...
201611191778.0
天津红日药业股份有限公司
郑玲玲
A61K 9/19
Loading...
本发明涉及一种苦柯胺B注射用组合物及其制备工艺和用途。通过对抗氧剂，金属离子螯合剂，冻干支持剂的筛选，得到一种苦柯胺B冷冻注射用制剂。该制剂冻干工艺简单，质量稳定，易于工业化生产，拟用于预防和治疗全身性炎症反应和自身免疫紊乱相关疾病，由于是脓毒症及相关疾病的治疗。
2. 106580909 一种含有盐酸沙格雷酯固体药物组合物
CN
26.04.2017
A61K 9/36 Loading...
A61K 9/36
Loading...
102016001190911
天津红日药业股份有限公司
魏征
A61K 9/36
Loading...
本发明涉及一种盐酸沙格雷酯口服固体组合物及其制备工艺和用途。通过对制剂中各辅料成分及用量的筛选，得到一种盐酸沙格雷酯包衣片剂，所得片剂崩解适宜，硬度、脆碎度等指标均达到包衣工艺要求，具有生产工艺简单，便于生产，质量稳定等特点。
3. 106543191 一种替格瑞洛制备工艺
CN
29.03.2017
C07D 487/04 Loading...
C07D 487/04
Loading...
201610968362.9
天津红日药业股份有限公司
刘畅
C07D 487/04
Loading...
本发明公开一种替格瑞洛制备工艺，通过在替格瑞洛制备过程中加入有机弱碱中和乙酸以及由乙酸乙酯降解生成的乙酸的方式，避免了替格瑞洛终产品中氧化杂质的产生，检测证明，原有终产品中的氧化杂质砜和亚砜被有效除去，本工艺大大提高了产品质量，并且工艺简单可行，适用于工业化生产。
4. 106344525 一种磷酸泰地唑胺冻干粉针
CN
25.01.2017
A61K 9/19 Loading...
A61K 9/19
Loading...
102016000980619
天津红日药业股份有限公司
郑玲玲
A61K 9/19
Loading...
本发明公开了一种磷酸泰地唑胺冻干粉针制剂处方及其制备方法，属药物制剂技术领域。本发明公开了每支磷酸泰地唑胺冻干粉针配液过程含：磷酸泰地唑胺200mg、甘露醇105mg，2ml注射用水。本发明要解决的技术问题是磷酸泰地唑胺不溶于水，而制剂需制备成冻干粉针制剂。
5. 104725278 一种苦柯胺B中间体的制备方法
CN
25.01.2017
C07C 271/20 Loading...
C07C 271/20
Loading...
102015000037201
天津红日药业股份有限公司
张存彦
C07C 271/20
Loading...
本发明提供一种苦柯胺B中间体KB‑III的制备方法。通过本发明制备KB‑III，由于在制备过程中，中间体KB‑II的直接进行氮气保护使得，使得KB‑III的收率大幅度的提高，并且缩短了后处理时间。节省了大量的人力物力。
6. WO/2016/202310 SULPHONATED PENTASACCHARIDE COMPOUND HAVING ANTI-XA FACTOR ACTIVITY
WO
22.12.2016
C07H 15/12 Loading...
C07H 15/12
Loading...
PCT/CN2016/095464
TIANJIN CHASE SUN PHARMACEUTICAL CO. LTD
GAN, Hao
C07H 15/12
Loading...
A sulphonated pentasaccharide compound having anti-Xa factor activity, and a preparation method and use for said compound. The compound is a derivative of a pentasaccharide compound having an anticoagulation effect, and has significant anti-Xa factor activity.
7. 105640876 一种盐酸莫西沙星氯化钠注射液的制备工艺
CN
08.06.2016
A61K 9/08 Loading...
A61K 9/08
Loading...
201610011014.2
天津红日药业股份有限公司
刘同亮
A61K 9/08
Loading...
本发明的目的在于提供一种质量更好，稳定性好、副作用少的莫西沙星氯化钠注射液的制备工艺。本发明所述盐酸莫西沙星注射剂的制备方法，包括以下步骤：步骤一：称量：按处方量分别称取盐酸莫西沙星和氯化钠，配制备用；步骤二：配液(1)：取注射用水，加入的盐酸莫西沙星，搅拌使完全溶解，加入药用炭，搅匀，搅拌吸附，滤膜除炭过滤，用适量注射用水冲洗炭层，滤液备用；步骤三：配液(2)：取注射用水，加入处方全量的氯化钠，搅拌使溶解完全，冷却，加入药用炭，搅匀，搅拌吸附，用滤膜除炭过滤，再用注射用水冲洗炭层，合并滤液，加的注射用水至全量，调节pH，搅匀，待灌装；步骤四：灌封：药液用的微孔滤膜滤过，滤液灌装于玻璃输液瓶中，充氮，加塞，轧盖，待灭菌。
8. 105606741 一种替格瑞洛的有关物质的含量检测方法
CN
25.05.2016
G01N 30/02 Loading...
G01N 30/02
Loading...
201610137235.4
天津红日药业股份有限公司
张存彦
G01N 30/02
Loading...
本发明的目的在于提供一种精密度高，操作简单，适用性强的替格瑞洛的有关物质的含量检测方法，包括以下步骤：(1)系统适用性溶液制备：取羟基物、氨基物、亚砜1和亚砜2、砜、光降解物、五元环羟基物、转位产物、乙酯化物、过程中间体3及替格瑞洛配制成系统适用性溶液；(2)供试品溶液制备：取替格瑞洛原料药配制成供试品溶液；(3)对照溶液的制备：取供试品溶液配制成对照溶液；(4)分别将系统适用性溶液、对照溶液和供试品溶液注入液相色谱仪，得到色谱图；(5)根据系统适用性溶液、对照溶液和供试品溶液的色谱图，经过计算得到供试品溶液中有关物质的含量。
9. 105418377 一种2-乙基-1,3-己二醇纯化工艺及有关物质检测方法
CN
23.03.2016
C07C 31/20 Loading...
C07C 31/20
Loading...
201610015628.8
天津红日药业股份有限公司
刘黄刚
C07C 31/20
Loading...
本发明属于医药技术领域，具体涉及一种2-乙基-1,3-己二醇的纯化工艺及其有关物质检测方法。本发明所述纯化工艺为氢化钙还原工艺。所述检测方法，包括以下步骤：步骤1，系统适用性溶液制备：取杂质1、杂质2、杂质3及2-乙基-1,3-己二醇配制成系统适用性溶液；步骤2，供试品溶液制备：取2-乙基-1,3-己二醇配制成供试品溶液；步骤3，对照溶液的制备：取供试品溶液配制成对照溶液；步骤4，分别将系统适用性溶液、对照溶液和供试品溶液注入气相色谱仪，得到色谱图；步骤5，根据系统适用性溶液、对照溶液和供试品溶液的色谱图，经过计算得到供试品溶液中各已知杂质、未知杂质及总杂质的含量。
10. 105348136 用于苦柯胺B质量控制中的参比化合物
CN
24.02.2016
C07C 235/34 Loading...
C07C 235/34
Loading...
201510504827.0
天津红日药业股份有限公司
董凯
C07C 235/34
Loading...
本发明涉及用于苦柯胺B质量控制中的三种参比化合物，及其制备方法，以及用此三种参比化合物控制苦柯胺B质量的质量控制方法。
11. 105330563 用于苦柯胺B质量控制中的参比化合物
CN
17.02.2016
C07C 235/34 Loading...
C07C 235/34
Loading...
201510655784.6
天津红日药业股份有限公司
董凯
C07C 235/34
Loading...
本发明涉及用于苦柯胺B质量控制中的四种参比化合物，及其制备方法，以及用此三种参比化合物控制苦柯胺B质量的质量控制方法。
12. 105301156 一种注射用特利加压素的有关物质分析方法
CN
03.02.2016
G01N 30/88 Loading...
G01N 30/88
Loading...
201510655783.1
天津红日药业股份有限公司
许磊
G01N 30/88
Loading...
本发明属于医药技术领域，具体涉及一种注射用特利加压素的有关物质分析方法。本发明所述的注射用特利加压素的含量检测方法，包括以下步骤：步骤1，供试品溶液的制备：取注射用特利加压素配制成供试品溶液；步骤2，自身对照品溶液制备：将供试品溶液稀释，配制成自身对照品溶液；步骤3，有关物质的含量计算：分别将对照品溶液和供试品溶液注入高效液相色谱仪，得到色谱图，计算得到供试品溶液中有关物质含量。
13. 105301121 一种苯酞类化合物的液-质联用检测方法
CN
03.02.2016
G01N 30/02 Loading...
G01N 30/02
Loading...
201410836714.6
天津红日药业股份有限公司
孙艳
G01N 30/02
Loading...
本发明公开了一种苯酞类化合物的液-质联用检测方法。该方法包括在高效液相色谱仪的流动相中加入一定量的含锂离子的有机化合物，使苯酞类化合物在电离后能够形成加锂的准分子离子峰，继而在给予一定能量下能被打碎产生特征性的碎片离子，通过检测准分子离子峰→子离子的离子通道实现高灵敏度的二级质谱检测。本发明可用于检测预处理后的生物样品或中药制剂样品中的苯酞类化合物，从而实现基于液-质联用技术的灵敏、特异、准确的分析。
14. 105301157 一种甲磺酸苦柯胺B有关物质检测方法
CN
03.02.2016
G01N 30/88 Loading...
G01N 30/88
Loading...
201510655785.0
天津红日药业股份有限公司
韩冬
G01N 30/88
Loading...
本发明涉及一种甲磺酸苦柯胺B有关物质质量控制方法，包括以下步骤：步骤1，系统适用性溶液制备：取杂质1、杂质2、杂质3及甲磺酸苦柯胺B配制成系统适用性溶液；步骤2，供试品溶液制备：取甲磺酸苦柯胺B原料药配制成供试品溶液；步骤3，对照溶液的制备：取供试品溶液配制成对照溶液；步骤4，分别将系统适用性溶液、对照溶液和供试品溶液注入液相色谱仪，得到色谱图；步骤5，根据系统适用性溶液、对照溶液和供试品溶液的色谱图，经过计算得到供试品溶液中各已知杂质、未知杂质及总杂质的含量。本发明所述的检测方法具有重现性好、准确度高等特点。
15. 105147627 一种含有盐酸普拉克索的药物组合物及其制备方法
CN
16.12.2015
A61K 9/20 Loading...
A61K 9/20
Loading...
201510512655.1
天津红日药业股份有限公司
魏征
A61K 9/20
Loading...
本发明涉及一种含有盐酸普拉克索的药物组合物及其制备方法，所述组合物是口腔崩解片，各组分配比如下：本发明的盐酸普拉克索口腔崩解片制备工艺简单，口感良好，与目前上市产品相比，有更好的服药顺应性，尤其适合老年人和吞咽困难者等特殊人群服用。
16. 105055351 一种替格瑞洛片剂组合物
CN
18.11.2015
A61K 9/20 Loading...
A61K 9/20
Loading...
201510481392.2
天津红日药业股份有限公司
何晓娟
A61K 9/20
Loading...
本发明涉及一种替格瑞洛片，其包含替格瑞洛以及药学上可接受的辅料；本发明的替格瑞洛片质量稳定、可控。
17. 105037452 一种快速制备高纯度磺达肝癸钠的精制方法
CN
11.11.2015
C07H 15/04 Loading...
C07H 15/04
Loading...
201510345431.6
天津红日药业股份有限公司
姚小青
C07H 15/04
Loading...
一种快速制备高纯度磺达肝癸钠的精制方法，本发明提供一种生产成本低，操作简单并且能达到高纯度和高回收率的制备方法。通过高效液相色谱制备法，可以将含量为50％以上的磺达肝癸钠粗品经过一次制备达到99％以上纯度。
18. 105001278 一种磺达肝癸钠二糖中间体片段的合成方法
CN
28.10.2015
C07H 15/04 Loading...
C07H 15/04
Loading...
201510344888.5
天津红日药业股份有限公司
姚小青
C07H 15/04
Loading...
本发明涉及一种磺达肝癸钠中间体二糖片段GH的合成方法。该方法可克服现有技术中的立体选择性差和产率低的缺点与不足，其立体选择性为100％，且收率大于70％。具有生产成本低，操作方便，生产设备选型容易，反应收率高，环境友好等优点。
19. 104977271 一种红花醇沉过程有效成分近红外在线检测方法
CN
14.10.2015
G01N 21/3577 Loading...
G01N 21/3577
Loading...
201410135941.6
天津红日药业股份有限公司
姚小青
G01N 21/3577
Loading...
本发明提供一种红花醇沉过程有效成分近红外在线检测方法，包括①近红外在线检测循环管路；②在线采集红花醇沉液的近红外透射光谱及醇沉液样本；③采用高效液相色谱法和烘干称重法测得醇沉液样本中各质控指标(包括羟基红花黄色素A和可溶性固形物含量)信息；④采用偏最小二乘算法建立各质控指标模型；⑤将所建模型用于在线分析醇沉过程中各质控指标的变化趋势。本发明将近红外光谱技术用于红花醇沉过程，采用流通池结合光纤探头的方式，实现了红花醇沉过程中羟基红花黄色素A和可溶性固形物含量的在线定量分析，为红花醇沉过程的在线控制提供依据及有效的指导。
20. 104473914 Sulfonamide drug combination
CN
01.04.2015
A61K 31/18 Loading...
A61K 31/18
Loading...
201510005995.5
天津红日药业股份有限公司
吴宜庄
A61K 31/18
Loading...
The invention discloses a sulfonamide drug combination and relates to a sulfonamide compound injection preparation. The sulfonamide drug combination comprises a sulfonamide compound or a derivate of the sulfonamide compound. The injection preparation is prepared by the sulfonamide compound and auxiliary materials acceptable in pharmacy through the certain preparation technology. The sulfonamide compound injection preparation is stable and controllable in quality and effective.
21. 104297375 一种中药血必净注射液中聚山梨酯80的含量检测方法
CN
21.01.2015
G01N 30/02 Loading...
G01N 30/02
Loading...
201410567353.X
天津红日药业股份有限公司
姚小青
G01N 30/02
Loading...
本发明属于医药技术领域，具体涉及一种中药血必净注射液中聚山梨酯80的气相色谱检测方法。本发明所述的检测方法，包括以下步骤：步骤1，对照品溶液制备：以聚山梨酯80为对照品，配制成对照品溶液；步骤2，供试品溶液的制备：取血必净注射液配制成供试品溶液；步骤3，分别将对照品溶液和供试品溶液注入气相色谱仪，得到色谱图；步骤4，根据色谱图对照品和供试品的色谱图，经过计算得到供试品溶液中的聚山梨酯80的含量。
22. 103940773 Method for rapidly measuring content of tween-80 in Xuebijing injection
CN
23.07.2014
G01N 21/3577 Loading...
G01N 21/3577
Loading...
201410140478.4
清华大学
梁琼麟
G01N 21/3577
Loading...
The invention discloses a method for rapidly measuring the content of tween-80 in a Xuebijing injection. The method comprises the following steps: (1) adding tween-80 with different masses into a Xuebijing injection, thereby preparing at least 15 Xuebijing injection standard substances containing tween-80 with different concentration; (2) acquiring near infrared spectrograms of the Xuebijing injection standard substances; (3) establishing a correction model between the content of tween-80 in the Xuebijing injection standard substances and the near infrared spectrograms by a chemometrics method; and (4) acquiring a near infrared spectrogram of a Xuebijing injection to be measured, and inputting the near infrared spectrogram into the correction model so as to obtain the content of tween-80 in the Xuebijing injection. The rapid measurement method can be used for rapid online measurement on an intermediate at the key production process point of the Xuebijing injection during a production process, and provides a real-time online rapid detection method for quality control on the production process.
23. 103655569 Use of N-(pyridine-4-yl) piperazine-1-formamide
CN
26.03.2014
A61K 31/496 Loading...
A61K 31/496
Loading...
201310648691.1
天津红日药业股份有限公司
肖保国
A61K 31/496
Loading...
The present invention relates to use of N-(pyridine-4-yl) piperazine-1-formamide in the preparation of a medicinal preparation for degenerative neuropathy. The degenerative neuropathy includes but is not limited to one or a plurality of Alzheimer's disease, Parkinson's disease and multiple sclerosis. The invention also relates to a synthesis method of the N-(pyridine-4-yl) piperazine-1-formamide.
24. 103601683 苯并杂环类化合物及其制备方法和用途
CN
26.02.2014
C07D 235/06 Loading...
C07D 235/06
Loading...
201310423211.1
中国科学院上海药物研究所
朱大元
C07D 235/06
Loading...
本发明提供一类非核苷类抗病毒抑制剂，具体为如通式I所示的苯并杂环类化合物或其药学上可接受的盐或水合物，本发明还提供了该类化合物或其药学上可接受的盐或水合物的制备方法。经药理试验表明该类化合物或其药学上可接受的盐或水合物能有效抑制乙肝病毒DNA复制和丙肝病毒RNA复制，因此本发明还提供了该类化合物在制备预防和/或治疗病毒性感染、特别是乙肝病毒(HBV)感染和丙肝病毒(HCV)感染的药物中的用途。
25. 103172634 Method for preparing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizinone-5-acetic acid-4'-bromo-butyl ester
CN
26.06.2013
C07D 487/04 Loading...
C07D 487/04
Loading...
201110433138.7
天津药物研究院
梅林雨
C07D 487/04
Loading...
The invention relates to a method for preparing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizinone-5-acetic acid-4'-bromo-butyl ester. The method comprises the following steps of: enabling 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizinone-5-acetic acid and 1,4-dibromobutane which serve as raw materials to react in an organic solvent under the catalysis of 1,8-diazabicyclo-bicyclo(5,4,0)-7-undecene serving as a catalyst to generate the 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizinone-5-acetic acid-4'-bromo-butyl ester. The method provided by the invention has the advantages that the reaction condition is mild, the materials can react at a high temperature at a high speed with less byproducts being generated, and the yield and the purity of the obtained target product are high, and method is suitable for industrial production.
26. 103083319 一种复方缬沙坦氨氯地平固体制剂的制备工艺
CN
08.05.2013
A61K 31/4422 Loading...
A61K 31/4422
Loading...
201310030527.4
天津红日药业股份有限公司
董凯
A61K 31/4422
Loading...
本发明属于医药技术领域，具体涉及一种复方缬沙坦氨氯地平固体制剂及其制备工艺和用途。本发明所述的制备工艺，包括以下步骤：1）采用流化床制粒工艺将氨氯地平溶解在乙醇水溶液中，雾化喷散于含有缬沙坦及药学上可接受辅料中，制备含两种主药的载药颗粒；2）缬沙坦粉碎过200目筛，以增大此原料的密度。
27. 103070824 一种含有伊班膦酸钠的注射液
CN
01.05.2013
A61K 9/08 Loading...
A61K 9/08
Loading...
201310026921.0
天津红日药业股份有限公司
董凯
A61K 9/08
Loading...
本发明涉及一种含有伊班膦酸钠的注射液，以伊班膦酸钠与药学上可接受的辅料制备成注射液，选用磷酸盐缓冲液控制注射液pH在3.5-4.5之间，同时以占溶液总体积0.1%的活性炭脱热原，在脱去热原的同时避免了活性炭对主药的吸附。通过加速稳定性试验，表明所得注射液杂质低于已上市注射液，并且质量稳定，可控。
28. 102993178 具有Rho激酶抑制活性的异喹啉类化合物、制备方法及用途
CN
27.03.2013
C07D 401/12 Loading...
C07D 401/12
Loading...
201210513304.9
天津红日药业股份有限公司
孙长海
C07D 401/12
Loading...
本发明公开了一种具有Rho激酶抑制活性的异喹啉类化合物、制备方法及用途，所述化合物结构如式（I）或（II）所示：本发明的化合物生物活性好，对靶点的作用强，细胞再生和突触形成能力强，在细胞活性测试中成活率高，在细胞凋亡测试中死亡率低，且一氧化氮毒性测试较低。
29. 102973571 法舒地尔的新用途
CN
20.03.2013
A61K 31/551 Loading...
A61K 31/551
Loading...
201210535633.3
天津红日药业股份有限公司
董凯
A61K 31/551
Loading...
本发明涉及法舒地尔的新用途。法舒地尔及其药用盐及水合物可用于制备治疗中、重度多发性硬化症的口服药物制剂。
30. 102949356 一种含有胸腺法新的冻干制剂
CN
06.03.2013
A61K 9/19 Loading...
A61K 9/19
Loading...
201210499830.4
天津红日药业股份有限公司
李宝齐
A61K 9/19
Loading...
本发明涉及一种含有胸腺法新的冻干制剂，以胸腺法新为活性成分与药学上可接受的辅料制备成冻干制剂。本发明在处方中加入叔丁醇，并采用醋酸盐缓冲溶液调节冻干前溶液pH值，缩短了冻干周期，抑制了在制备过程中主药的降解，提高了主药的稳定性，保证了产品的质量。
31. 102949339 一种含有罗库溴铵的注射剂
CN
06.03.2013
A61K 9/08 Loading...
A61K 9/08
Loading...
201210501837.5
天津红日药业股份有限公司
李宝齐
A61K 9/08
Loading...
本发明涉及一种含有罗库溴铵的注射剂，以罗库溴铵为活性成分与药学上可接受的载体为辅料制备成注射剂。本发明通过加入1%-5%的醋酸盐缓冲溶液来维持体系的pH值，在维持体系pH值的同时，增加了溶液的稳定性，抑制了在制备过程中主药的降解，提高了主药的稳定性，减少了在热压灭菌过程中罗库溴铵杂质C产生的数量。最终，得到了稳定性良好，质量稳定，适合长期储存的罗库溴铵注射剂。
32. 102908323 一种含有莫西沙星的药物组合物
CN
06.02.2013
A61K 9/20 Loading...
A61K 9/20
Loading...
201210422473.1
天津红日药业股份有限公司
李宝齐
A61K 9/20
Loading...
本发明涉及一种含有莫西沙星的药物组合物，以莫西沙星与药学上可接受的辅料组成固体药物组合物，该组合物可以通过本发明的技术方案制备成口服固体制剂，通过在处方中加入金属离子螯合剂，避免了在固体制剂生产过程中红色莫西沙星金属离子螯合物的产生，从而提高了莫西沙星片剂的稳定性，同时该固体制剂具有与进口上市片剂相似的溶出的溶出行为，硬度，此制备处方和工艺质量稳定、可控。
33. 102464591 苦柯胺B盐及制备方法和用途
CN
23.05.2012
C07C 235/34 Loading...
C07C 235/34
Loading...
201010539028.4
中国人民解放军第三军医大学第一附属医院
郑江
C07C 235/34
Loading...
本发明涉及一种苦柯胺B盐，以及其制备方法和在制备预防和治疗脓毒症药物中的用途。实验显示，苦柯胺B盐对介导脓毒症的主要致病因子具有良好的拈抗作用，可用于制备预防和治疗脓毒症的药物。苦柯胺B盐与药学上可接受的任何载体和/或稀释剂制成各种制剂，在目前临床上缺乏确切有效的脓毒症治疗措施的情况下，为此类难治性疾病提供了一种有效的防治手段。
34. 102464660 6-(4-氯苯基)-2,2-二甲基-7-苯基-2,3-二氢基-吡咯哩嗪-5-乙酸硝酸丁酯晶体及其制备方法和应用
CN
23.05.2012
C07D 487/04 Loading...
C07D 487/04
Loading...
201010536653.3
天津药物研究院
梅林雨
C07D 487/04
Loading...
本发明公开了一种6-(4-氯苯基)-2，2-二甲基-7-苯基-2，3-二氢基-吡咯哩嗪-5-乙酸硝酸丁酯的晶体，所述晶体的晶胞参数为：α＝90.00°，β＝96.272(4)°，γ＝90.00°，Z＝4，晶胞体积此外，本发明还公开了所述晶体的制备方法以及它们在制备药物，特别是制备非甾体解热镇痛、抗关节炎、保护胃肠道粘膜药物中的应用。
35. 102464659 利可瑞特化合物结晶形态、其制备方法及用途
CN
23.05.2012
C07D 487/04 Loading...
C07D 487/04
Loading...
201010536652.9
天津药物研究院
梅林雨
C07D 487/04
Loading...
本发明提供自身免疫调节药物6-(4-氯苯基)-2，2-二甲基-7-苯基-2，3-二氢基-吡咯哩嗪-5-乙酸硝酸丁酯(利可瑞特)的两种新结晶形态、所述结晶形态在制备用于解热、镇痛、抗关节炎药物方面的应用、含有所述结晶形态的药物组合物以及所述6-(4-氯苯基)-2，2-二甲基-7-苯基-2，3-二氢基-吡咯哩嗪-5-乙酸硝酸丁酯两种结晶形态的制备方法。
36. WO/2012/062026 SALTS OF KUKOAMINE B, PREPARATION METHOD AND USE THEREOF
WO
18.05.2012
C07C 35/34 Loading...
C07C 35/34
Loading...
PCT/CN2011/000479
THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL UNIVERSITY, PLA
ZHENG, Jiang
C07C 35/34
Loading...
Provided are salts of kukoamine B, their preparation method and their use in preventing and treating sepsis diseases.
37. 102367257 氯吡格雷盐酸盐的单晶晶型,它们的制备及应用
CN
07.03.2012
C07D 495/04 Loading...
C07D 495/04
Loading...
201110370384.2
天津红日药业股份有限公司
姚小青
C07D 495/04
Loading...
本发明涉及氯吡格雷盐酸盐的单晶晶型，它们的制备及应用，所述单晶晶型为单斜晶系，其晶轴：a=9.2985(5)，b=8.8930(4)，c=21.2663(15)；晶面间夹角α＝90°，β＝101.575(5)°，γ＝90°，另外本发明还涉及了这种单晶构型的药物组合物用于治疗预防动脉粥样硬化血栓形成。
38. 102285996 Benzenesulfonic acid clopidogrel crystal form II, preparation method and application thereof
CN
21.12.2011
C07D 495/04 Loading...
C07D 495/04
Loading...
201110078054.6
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
C07D 495/04
Loading...
The invention relates to the technical field of medicines, in particular to a benzenesulfonic acid clopidogrel crystal form II, a preparation method thereof, medicinal composition containing the same and an application thereof in manufacturing an anti-platelet-aggregation medicine. The benzenesulfonic acid clopidogrel crystal form I uses Cu-Ka for radiation, and the X-ray powder diffraction shown by 2theta degrees has peaks at 2theta degrees, namely 14.400 degrees, 16.380 degrees, 17.200 degrees, 21.100 degrees, 21.440 degrees, 22.020 degrees, 23.240 degrees and 24.580 degrees.
39. 102276521 Kukoamine B analogue, and pharmaceutically acceptable salt, preparation method and application thereof
CN
14.12.2011
C07D 213/69 Loading...
C07D 213/69
Loading...
201110164238.4
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
C07D 213/69
Loading...
The invention relates to a kukoamine B analogue having a structure shown as the formula (1) or a pharmaceutical salt thereof, and a preparation method and application thereof. In the formula (1), R1, R2, R3 and R4 can independently be H, alkyl with less than 3 carbon atoms and protective groups of hydroxyls, such as formoxyl, ethanoyl, benzyl and the like; X1-X3 can independently be C atom or N atom; when one is the N atom, other two are the C atoms; X4-X6 can independently be the C atom or the N atom; when one is the N atom, other two are the C atoms; and n1-n5 can independently be alkyl with less than 4 carbon atoms.
40. 102252992 Method for performing near-infrared on-line detection in process of extracting Chinese medicines
CN
23.11.2011
G01N 21/359 Loading...
G01N 21/359
Loading...
201110109187.5
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
G01N 21/359
Loading...
The invention relates to a method for performing near-infrared on-line detection in the process of extracting Chinese medicines. The method comprises the following steps of: installing a near-infrared on-line detection system; 2, collecting Chinese medicine extracting solution and measuring near infrared spectrum; 3, measuring various technical indexes of the extracting solution sample by the known analysis method; 4, establishing a corresponding relationship between spectroscopic data acquired in the step 2 and various technical indexes measured in the step 3, so that various technical indexes of the extracting solution can be acquired from the spectroscopic data; and 5, monitoring the Chinese medicine extraction process in the actual production.
41. WO/2011/134271 USE OF KUKOAMINE A AND KUKOAMINE B
WO
03.11.2011
A61K 31/165 Loading...
A61K 31/165
Loading...
PCT/CN2011/000478
THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL UNIVERSITY, PLA
ZHENG, Jiang
A61K 31/165
Loading...
Use of kukoamine A and kukoamine B in preparing medicine for preventing and treating sepsis and autoimmune diseases. The kukoamine A and kukoamine B are extracted from cortex lycii radicis. The medicine is used for antagonism of bacterial endotoxin (LPS) and bacteria non-methylated DNA (CpG DNA).
42. WO/2011/127833 BENZOHETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF
WO
20.10.2011
C07D 209/16 Loading...
C07D 209/16
Loading...
PCT/CN2011/072816
SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
ZHU, Dayuan
C07D 209/16
Loading...
A kind of non-nucleoside antiviral inhibitors, more especially, benzoheterocyclic compounds shown as general formula I or their pharmaceutically acceptable salts or hydrates and preparation methods thereof are provided. These compounds or their pharmaceutically acceptable salts or hydrates can inhibit hepatitis B virus (HBV) DNA replication and hepatitis C virus (HCV) RNA replication, and can be used in the manufacture of medicaments for preventing and/or treating viral infections, especially HBV infections and HCV infections.
43. 102219725 Benzohetercyclic compound as well as preparation method and applications thereof
CN
19.10.2011
C07D 209/16 Loading...
C07D 209/16
Loading...
201010149856.7
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Zhu Dayuan
C07D 209/16
Loading...
The invention provides a non-nucleoside antiviral inhibitor, especially a benzohetercyclic compound shown by a general formula I or pharmaceutically acceptable salt or hydrate. The invention further provides a method for preparing the compound or the pharmaceutically acceptable salt or hydrate. Pharmacology tests show that the compound or salt or hydrate accepted on the pharmacy can effectively inhibit replication of HBV (hepatitis B virus) DNA (deoxyribonucleic acid) and HCV (hepatitis C virus) RNA (Ribonucleic acid), therefore, the invention further provides applications on preparing medicaments in preventing and/or treating viral infection, especially the HBV and the HCV. The general formula I is as follows.
44. 102204917 Pharmaceutical composition containing fasudil and sildenafil, and preparation method and application thereof
CN
05.10.2011
A61K 31/551 Loading...
A61K 31/551
Loading...
201110078003.3
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 31/551
Loading...
The invention relates to a pharmaceutical composition containing fasudil and sildenafil for treating pulmonary hypertension, and a preparation method thereof, belonging to the field of pharmacy. The composition provided by the invention uses fasudil and sildenafil as the pharmaceutical active components, and the composition also comprises other pharmaceutically acceptable carriers, such as a disintegrant, an adhesive, an excipient, a thinner, a lubricant, a skeletal material for controlling the release rate of the active components in a sustained or controlled release preparation, and the like, and the suitable carriers are selected for different dosage forms.
45. 102199123 New crystal form and pharmaceutical application of fasudil
CN
28.09.2011
C07D 217/02 Loading...
C07D 217/02
Loading...
201010130620.9
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
C07D 217/02
Loading...
The invention relates to a new crystal form and pharmaceutical application of fasudil, particularly to a crystal form of fasudil hydrochloride. The new crystal form of fasudil hydrochloride is characterized by having the following spectroscopic characteristics that the crystal phase of a sample is analyzed by a Rigaku D/max-2500 X-ray powder diffraction (XRD) instrument with a Cu Kalpha target at a tube voltage of 40 kV and a tube current of 100 mA, and the X-ray powder diffraction of the sample has the following characteristic peaks: peaks exist at angles 2theta which are about 6.780 DEG, 14.700 DEG, 16.620 DEG, 17.480 DEG, 20.440 DEG, 20.740 DEG and 24.52 DEG.
46. 102198274 Raloxifene cyclodextrin inclusion compound and preparation method of preparation of raloxifene cyclodextrin inclusion compound
CN
28.09.2011
A61K 47/48 Loading...
A61K 47/48
Loading...
201110078021.1
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 47/48
Loading...
The invention relates to a raloxifene cyclodextrin inclusion compound. The inclusion compound consists of raloxifene or medicinal salt thereof, cyclodextrin and an antioxidant, wherein the raloxifene medicinal salt is selected from hydrochloride, sulfate, phosphate, nitrate, fumarate, tartrate or succinate of raloxifene, the cyclodextrin is sulfobutylether-beta-cyclodextrin, the ratio by mass of the raloxifene medicinal salt to the cyclodextrin is 1:(1-9), and the antioxidant is vitamin E.
47. 102199161 Benzene sulfonic acid clopidogrel with crystal form I, preparation method thereof and application thereof
CN
28.09.2011
C07D 495/04 Loading...
C07D 495/04
Loading...
201110078013.7
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
C07D 495/04
Loading...
The invention relates to the technical field of medicine, and concretely relates to benzene sulfonic acid clopidogrel with a crystal form I, a preparation method thereof, a pharmaceutical composition containing the benzene sulfonic acid clopidogrel with the crystal form I and an application for preparing platelet arrogation inhibitors. The present invention aims to provide the benzene sulfonic acid clopidogrel with the crystal form I which has good stability and repeatability. No characteristic absorption peak appears with an X-ray powder diffractometer, the benzene sulfonic acid clopidogrel with the crystal form I has absorption peaks at temperatures of 123 DEG C and 257 DEG C with a differential scanning calorimeter, and infrared absorption peaks appear at 3442.31 cm<-1>, 2967.91 cm<-1>, 2578.36 cm<-1>, 1754.90 cm<-1>, 1641.13 cm<-1>, 1446.35 cm<-1> and 613.25 cm<-1>.
48. 102188433 Compound preparation of Fasudil and Beraprost as well as preparation method and application thereof
CN
21.09.2011
A61K 31/551 Loading...
A61K 31/551
Loading...
201110078051.2
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 31/551
Loading...
The invention belongs to the pharmaceutical field and relates to a compound preparation of Fasudil and Beraprost as well as a preparation method and application thereof to treating pulmonary hypertension. The compound preparation in the invention comprises Fasudil, Beraprost and auxiliary materials chosen from auxiliary materials acceptable in pharmacy, such as a disintegrating agent, an adhesive, an excipient, diluents, a lubricant, framework materials used for controlling the release of active ingredients in slow and controlled release agents, and the like. Proper carriers are chosen according to different types of drugs.
49. 102178682 Fasudil and Vardenafil compound preparation and preparation method thereof
CN
14.09.2011
A61K 31/551 Loading...
A61K 31/551
Loading...
201110078005.2
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 31/551
Loading...
The invention belongs to the field of pharmacy and relates to a Fasudil and Vardenafil compound preparation and a preparation method thereof. The Fasudil and Vardenafil compound preparation is used for treating pulmonary hypertension. The Fasudil and Vardenafil compound preparation comprises Fasudil, Vardenafil and pharmaceutically acceptable auxiliary materials such as skeleton materials and the like in a disintegrating agent, an adhesive, an excipient, a diluent, a lubricant and a sustained release preparation, wherein suitable carriers can be selected according to different formulations.
50. 102144971 Fasudil-containing oral spray or aerosol
CN
10.08.2011
A61K 9/12 Loading...
A61K 9/12
Loading...
201110079272.1
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 9/12
Loading...
The invention relates to fasudil-containing oral spray or aerosol in which active constituents can be quickly absorbed through the mouth mucosa to work quickly; and the spray or the aerosol has the advantages that the spray or the aerosol is high in bioavailability, excellent in compliance, portable, convenient to use and the like. The spray or the aerosol comprises the following constituents: fasudil hydrochloride, and pharmaceutically acceptable accessories selected from buffering agent, osmotic pressure regulator, flavoring agent, preservative, absorbefacient, antioxidant, bioadhesive agent, pH modifier, dissolvent and the like.
51. 102139115 Preparation method for atorvastatin cyclodextrin inclusion compound and oral solid preparation thereof
CN
03.08.2011
A61K 47/48 Loading...
A61K 47/48
Loading...
201110078062.0
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 47/48
Loading...
The invention belongs to the field of pharmacy and relates to an atorvastatin cyclodextrin inclusion compound and a preparation method thereof. The inclusion compound can be prepared into oral solid preparations for treating hyperlipidemia. The inclusion compound consists of atorvastatin or medicinal salt thereof and cyclodextrin. The atorvastatin medicinal salt is selected from sodium salt, calcium salt, potassium salt, ion salt and magnesium salt, the cyclodextrin is sulfo butyl-beta-cyclodextrin, and the mass ratio of the atorvastatin to the cyclodextrin is 1: (1-9).
52. 102138895 Eyedrops containing fasudil hydrochloride and preparation method thereof
CN
03.08.2011
A61K 9/08 Loading...
A61K 9/08
Loading...
201110079259.6
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 9/08
Loading...
The invention belongs to the technical field of medicines, and particularly relates to eyedrops containing fasudil hydrochloride and a preparation method thereof. The eyedrops containing the fasudil hydrochloride, which can reduce irritation, contain pharmaceutically-acceptable auxiliary materials such as fasudil hydrochloride, a thickener, a pH regulator, a bacteriostat, an isotonic agent, an antioxidant, substances for reducing eye irritation, and the like.
53. 102138901 Nasal spray or aerosol containing Fasudil
CN
03.08.2011
A61K 31/551 Loading...
A61K 31/551
Loading...
201110079281.0
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 31/551
Loading...
The invention relates to a nasal spray or aerosol containing Fasudil. The active component in the preparation can be absorbed rapidly through the nasal mucosa so that the response is rapid. The nasal spray or aerosol has the advantages of high bioavailability and good compliance, and is convenient in use and carrying. The preparation provided by the invention contains Fasudil hydrochloride and pharmaceutically acceptable excipients.
54. 102120745 Crystal form I of clopidogrel hydrochloride and preparation method and application thereof
CN
13.07.2011
C07D 495/04 Loading...
C07D 495/04
Loading...
201110033035.1
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
C07D 495/04
Loading...
The invention relates to the technical field of medicine, in particular to clopidogrel hydrochloride or a crystal form I of the clopidogrel hydrochloride and a preparation method thereof, a medicinal composition containing the crystal form I and application of the crystal form I in preparation of anti-platelet aggregation medicines. The crystal form I of the clopidogrel hydrochloride has peaks at 12.960 DEG, 19.860 DEG, 23.020 DEG, 24.920 DEG and 25.340 DEG represented by a 2theta angle in X-ray powder diffraction by using Cu-Ka radiation.
55. 102120746 Clopidogrel hydrochloride crystal form II as well as preparation method and application thereof
CN
13.07.2011
C07D 495/04 Loading...
C07D 495/04
Loading...
201110033048.9
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
C07D 495/04
Loading...
The invention relates to a novel crystal form of a compound, in particular to a clopidogrel hydrochloride crystal form II as well as a preparation method and application thereof. In the clopidogrel hydrochloride crystal form II presented by the invention, X-powder diffraction has the characteristic peaks in 2-theta angles of 8.900 degrees, 14.860 degrees, 16.760 degrees, 18.680 degrees, 23.240 degrees, 24.700 degrees, 25.080 degrees, 26.380 degrees and 26.940 degrees.
56. 102070648 Preparation method of clopidogrel hydrogen sulfate I
CN
25.05.2011
C07D 495/04 Loading...
C07D 495/04
Loading...
201010576242.7
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
C07D 495/04
Loading...
The invention relates to a preparation method of a drug compound, in particular to a preparation method of clopidogrel hydrogen sulfate I. The method provided by the invention comprises the following steps: 1, mixing clopidogrel salt with an organic solvent and water, adding an acid binding agent to react to generate free alkali of clopidogrel, extracting the water layer with the organic solvent, combining the organic phases and carrying out concentration; and 2. adding the organic solvent into the free alkali of clopidogrel obtained after concentration, dropwise adding sulfuric acid into the solution for reaction based on the molar ratio of the sulfuric acid to the free alkali of clopidogrel, filtering the reactant and drying the filtrate to obtain the crystal form of clopidogrel hydrogen sulfate I, wherein the molar ratio is (0.8-1.05):1.
57. 102060845 Fasudil crystal formation III as well as preparation method and application thereof
CN
18.05.2011
C07D 401/12 Loading...
C07D 401/12
Loading...
201010622364.5
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
C07D 401/12
Loading...
The invention particularly relates to a Fasudil crystal formation III as well as a preparation method and application thereof, belonging to the technical field of medicines. For the Fasudil hydrochloride V crystal formation, Cu-Ka radiation is adopted, and X-ray powder represented by an angle of 2 theta is diffracted by angles of 6.480, 13.620, 14.780, 16.700, 20.500, 20.800, 21.540, 24.580 and 25.540 degrees, wherein the angle of 2 theta has a characteristic peak. The Fasudil hydrochloride crystal formation prepared with the preparation method provided by the invention has the advantages of high bioavailability, obvious drug effect, good stability, high yield rate, high purity and the like, and is suitable for industrial production. The invention also further discloses the application of the Fasudil hydrochloride in improving and preventing of ischemic cranial vascular diseases caused by various reasons.
58. 102060844 Fasudil crystal formation IV as well as preparation method and application thereof
CN
18.05.2011
C07D 401/12 Loading...
C07D 401/12
Loading...
201010622357.5
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
C07D 401/12
Loading...
The invention particularly relates to a Fasudil crystal formation IV as well as a preparation method and application thereof, belonging to the technical field of medicines. For the Fasudil hydrochloride V crystal formation, Cu-Ka radiation is adopted, and X-ray powder represented by an angle of 2 theta is diffracted by angles of 6.320, 14.240, 14.460, 17.040, 22.640, 22.940, 25.400, 25.700 and 28.100 degrees, wherein the angle of 2 theta has a characteristic peak. The Fasudil hydrochloride crystal formation prepared with the preparation method provided by the invention has the advantages of high physical stability, high purity and the like when being stored and used at normal temperature and is further suitable for industrial production. The invention further discloses the application of the Fasudil hydrochloride in improving and preventing of ischemic cranial vascular diseases caused by various reasons.
59. 102028694 Application of Fasudil in preparing medicaments for treating glaucoma through ophthalmic drug delivery
CN
27.04.2011
A61K 31/551 Loading...
A61K 31/551
Loading...
201010547768.2
Tianjin Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 31/551
Loading...
The invention relates to the application of Fasudil in preparing medicaments for treating glaucoma through ophthalmic drug delivery, which belongs to the technical field of medicines. The Fasudil comprises pharmaceutically acceptable saline forms such as hydrochloride, nitrate, sulfate, phosphate, hydrobromide, mesylate, citrate and the like as well as pharmaceutically acceptable forms such as crystallization form, hydrate form and the like. The medicament is a pharmaceutic preparation composition prepared by using the Fasudil as an active pharmaceutical ingredient.
60. 102026643 The use and method of the compound of fasudil and the pharmaceutical composition thereof
CN
20.04.2011
A61K 31/551 Loading...
A61K 31/551
Loading...
200980122964.0
Tianjin Chasesun Pharmaceutica
Xiao Baoguo
A61K 31/551
Loading...
The present inventon provides a new use of fasudil in inducing the regeneration of adult brain neural stem cells and /or protecting the neurological functions, and in preventing and/or treating diseases related to damages and/or death of neuron. The use of fasudil in the present invention includes the use in manufacturing medicants for inducing the regeneration of adult brain neural stem cells and /or protecting the neurological functions. Moreover, the use of fasudil in manufacturing medicants for preventing and/or treating diseases related to damages and/or death of neuron.
61. 102008487 Application of Fasudil in preparing drug for treating pulmonary hypertension by atomized inhalation
CN
13.04.2011
A61K 31/551 Loading...
A61K 31/551
Loading...
201010547767.8
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 31/551
Loading...
The invention belongs to the technical field of medicine, particularly relating to an application of Fasudil in preparing a drug for treating pulmonary hypertension by atomized inhalation. The Fasudil comprises the modes of pharmaceutically acceptable salts, such as hydrochloride, nitrate, sulphate, phosphate, hydrobromide, mesylate, citrate and the like of the Fasudil, and comprises the pharmaceutically acceptable modes, such as a crystallization mode, a hydrate mode and the like of the Fasudil. The drug is a drug preparation composition prepared by taking the Fasudil as the drug active ingredient.
62. 101985444 V crystal form of Fasudil hydrochloride and preparation method and application thereof
CN
16.03.2011
C07D 401/12 Loading...
C07D 401/12
Loading...
201010258730.3
Tianjin Chasesun Pharmaceutical Co., Ltd.
Zhang Cunyan
C07D 401/12
Loading...
The invention belongs to the technical field of medicines, and in particular relates to a V crystal form of Fasudil hydrochloride and a preparation method and application thereof. For the V crystal form of the Fasudil hydrochloride, under Cu-Ka radiation and through X-ray powder diffraction represented by a 2 theta angle, the V crystal form has characteristic peaks at the wavelength of 6.260, 8.300, 14.020, 20.960, 23.860, 25.580 and 27.020. The preparation method provided by the invention ensures that the product has high purity and low impurity content, and is more suitable for industrial production. The invention also discloses application of the Fasudil hydrochloride in improving and preventing ischemic cerebrovascular disease brought by various causes.
63. 101829075 Applications of kukoamine A and kukoamine B
CN
15.09.2010
A61K 31/165 Loading...
A61K 31/165
Loading...
201010156503.X
The First Affiliated Hospital of the Third Military Medical University of PLA
Cao Hongwei
A61K 31/165
Loading...
The invention relates to applications of kukoamine A and kukoamine B in preparing medicines for preventing and treating pyemia and autoimmune diseases. The invention takes the main pathogen molecules bacterial lipopolysaccharide (LPS) and bacterial nonmethylated DNA (CpG DNA) which induce the pyemia and the autoimmune diseases as target spots, directionally separates medicine lead compounds from traditional Chinese medicines, overcomes the main defect of uncertain material basis and effect target spots of the components and extracts of the existing traditional Chinese medicines, and develops a safe, effective and new medicine with controllable quality to solve the problem of lack of effective therapeutic medicines for the pyemia and the autoimmune disease at present.
64. 101768190 Improvement method for refining and extracting technique in production process of fosphenytoin sodium intermediate
CN
07.07.2010
C07F 9/6506 Loading...
C07F 9/6506
Loading...
201010104658.9
Tianjian Chasesun Pharmaceutical Co., Ltd.
Wang Chengrui
C07F 9/6506
Loading...
The invention relates to an improvement method for refining and extracting technique for intermediate of bulk drug, in particular to an improvement method for refining technique in production process of bulk drug osphenytoin sodium applied in epilepsy resisting and eclampsia resisting medicines. The improvement method comprises the following steps: step 1, dissolving 3-chloromethyl-5,5-diphenyl dilantin in hot toluene, adding dibenzyl silver phosphate solid in parts, keeping at 40-80 DEG C for 3-10h, after reaction is finished, filtering while hot, reduced pressure concentrating the filtrate and recycling all the toluene; step 2, adding absolute ethyl alcohol into concentrate, agitating at 0-20 DEG C until precipitating white solid, standing in low temperature for 4-8h, filtering, washing with cold ethanol to obtain white 3-hydroxymethyl-5,5-diphenyl dilantin dibenzyl phosphate solid.
65. 101723934 Method for refining fasudil hydrochloride
CN
09.06.2010
C07D 401/12 Loading...
C07D 401/12
Loading...
200910224197.6
Tianjin Chasesun Pharmaceutical Co., Ltd.
Li Xuegai
C07D 401/12
Loading...
The invention relates to a method for refining fasudil hydrochloride. The method comprises the following steps: 1, discoloring, namely adding active carbon into fasudil after resin adsorption, fully mixing the active carbon and the fasudil, filtering the mixture, removing the active carbon, and collecting the filtered solution for later use; 2, washing, namely adding purified water into the discolored solution, fully mixing the solution, separating the solution to remove water phase, and collecting the oil phase for later use; 3, acidifying and salifying, namely adding the purified water into the oil phase, adjusting pH value of the solution by hydrochloric acid to fully acidify and salify the oil phase, and collecting the water phase for later use; and 4, crystallization, namely, adding n-butyl alcohol into the water phase, fully mixing the solution, then decompressing and azeotropic-crystallizing the solution, duly replenishing the n-butyl alcohol to keep the consistency of the solution, stopping crystallization till the moisture content in the mother solution is reduced to a certain value, and filtering and drying the crystals to obtain a refined fasudil hydrochloride product.
66. 101612157 Application of fasudil on leading adult brain endogenous neural stem cells to be regenerated
CN
30.12.2009
A61K 31/551 Loading...
A61K 31/551
Loading...
200810126351.1
Tianjin Chasesun Pharmaceutical Co., Ltd.
Xiao Baoguo
A61K 31/551
Loading...
The invention discloses the application of a fasudil and a medical compound containing the fasudil on leading adult brain endogenous neural stem cells to be regenerated. The invention in particular discloses the application of the fasudil on protecting nerve injury and treating diseases relevant to neurone injury and death.
67. WO/2009/155777 THE USE AND METHOD OF THE COMPOUND OF FASUDIL AND THE PHARMACEUTICAL COMPOSITION THEREOF
WO
30.12.2009
A61K 31/551 Loading...
A61K 31/551
Loading...
PCT/CN2009/000509
TIANJIN CHASESUN PHARMACEUTICAL CO., LTD
XIAO, Baoguo
A61K 31/551
Loading...
A new use of fasudil in inducing the regeneration of adult brain neural stem cells and /or protecting the neurological functions, and in preventing and/or treating diseases related to damages and/or death of neuron. The use of fasudil in the present invention includes the use in manufacturing medicants for inducing the regeneration of adult brain neural stem cells and /or protecting the neurological functions. Moreover, the use of fasudil in manufacturing medicants for preventing and/or treating diseases related to damages and/or death of neuron.
68. 101332217 Drying method of compound traditional Chinese medicine Xuebijin monarch drug extract
CN
31.12.2008
A61K 36/286 Loading...
A61K 36/286
Loading...
200810132726.5
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 36/286
Loading...
The invention relates to a drying method of traditional Chinese medicine extract, particular to the drying method adopted in the extracting and preparing process of safflower which is monarch drug in a prescription of a compounded medication of Xuebijing.
69. 101317893 Xuebijing oral administration effervescing agent
CN
10.12.2008
A61K 9/46 Loading...
A61K 9/46
Loading...
200810132727.X
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 9/46
Loading...
The present invention relates to a traditional Chinese medicine oral preparation, in particular to a hematic oral effervescing agent and a preparation method thereof. The hematic oral effervescing agent of the present invention is made from medical active substance, an alkaline matter, an acidic material, lactose and aerosil, wherein, the active substance is made from safflower, red peony root, Szechwan lovage rhizome, red rooted salvia root and angelica which are extracted and processed.
70. 101008637 Quality control method of fasudil hydrochloride injection
CN
01.08.2007
G01N 33/15 Loading...
G01N 33/15
Loading...
200710000226.1
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
G01N 33/15
Loading...
This invention relates to alcaine telfairic injection liquid quality control method, which comprises the following steps: property observing, content identifying; content testing and testing component volume.
71. 101007072 Quality-control method of a traditional Chinese medicine 'Xuebijing' injection
CN
01.08.2007
A61K 36/71 Loading...
A61K 36/71
Loading...
200710000288.2
Tianjian Chasesun Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 36/71
Loading...
The invention discloses a method for controlling quality of Chinese medicinal preparation Xuebijing for injection, which comprises steps of deseription observation, content identification, content examination, fingerprint pattern comparison, and content measurement for the constituents.
72. 2851157 注射液包装塑托
CN
27.12.2006
B65D 81/133 Loading...
B65D 81/133
Loading...
200520026790.7
天津红日药业股份有限公司
姚小青
B65D 81/133
Loading...
本实用新型属于针剂包装装置，特别是涉及一种注射液包装塑托。包装塑托的各瓶状凹槽由瓶颈凹槽和瓶体凹槽构成，瓶体凹槽的槽底设有轴向的键形缓冲槽。本包装塑托所设置的键形缓冲槽以及相对于瓶底的部位的辅助缓冲槽、塑盖表面凸起均使其抗振动性能得到明显改善，尤其是键形缓冲槽显著提高了瓶体凹槽的塑变能力，对剧烈振动产生的冲击力具有突出的吸收和缓解效果，因此可以有效避免或减少玻璃包装小瓶在剧烈振动下的破损。本实用新型具有结构简单、防破损作用显著的突出优点。
73. 1844121 Antipyretic analgesic and anti-arthritis nonsteroidal compound and its pharmaceutical compositions
CN
11.10.2006
C07D 487/04 Loading...
C07D 487/04
Loading...
200610013211.4
Tianjin Institute of Pharmaceutical Research
Mei Linyu
C07D 487/04
Loading...
The invention relates a group of compounds having formula (I) and their use as medicaments for non-steroidal analgesic analgesia, anti-arthritis, and protecting gastrointestinal tract mucous membrane. The invention also discloses the pharmaceutical compositions containing the compounds of formula (I), wherein R1, R2, R3 and X are defined in the specification.
74. 1813762 Fasudic hydrochloride oral formulation
CN
09.08.2006
A61K 31/551 Loading...
A61K 31/551
Loading...
200510130096.4
Tianjin Hongri Pharmaceutical Co., Ltd.
Yao Xiaoqing
A61K 31/551
Loading...
The present invention relates to a fashudil hydrochloride oral preparation for curing ischemic cerebrovascular disease due to cerebrovascular spasm after subarachnoid hemorrhage. It can be made into tablet, capsule and granule preparation.
75. 2697021 小瓶类被包装物包装用联体内置托架
CN
04.05.2005
B65D 81/133 Loading...
B65D 81/133
Loading...
200420028641.X
天津红日药业股份有限公司
姚小青
B65D 81/133
Loading...
本实用新型属于包装装置，特别是涉及一种小瓶类被包装物包装用联体内置托架。小瓶类被包装物的联体内置托架周遍凸棱、中间并列的瓶状凹槽和横贯并列瓶状凹槽的抠取凹槽所组成，其联体内置托架并列的各瓶状凹槽设有卧置被包装物瓶底的瓶底卧槽。在使用被包装物时，可以先将被包装物由其瓶底直立于瓶底卧槽，能够避免在作准备工作时被包装物的滚落破损。特别是在使用多种被包装物形状相同或近似而内装物质不同时的混淆，这一特点对于医院住院部病房配药工作尤其具有实际意义。本实用新型具有结构简单、作用显著的突出优点。
76. 1457851 Chinese medicine formula with treating and health function
CN
26.11.2003
A61K 36/75 Loading...
A61K 36/75
Loading...
03131120.2
Hongri Pharmaceutical Co., Ltd., Tianjin
Yao Xiaoqing
A61K 36/75
Loading...
The present invention provides a recipe of a kind of Chinese medicine with treating and health care functions. The present invention provides a Chinese medicine preparation prepared with safflower, red peony root, Chuanxiong rhizome, red sage, angelica, peach kernel and other Chinese medicinal materials. The preparation has the functions of antagonizing endotoxin, tumor necrosis factor and inflammatory mediator, and may be used in preventing and treating pyaemia and multiple-organ malfunction syndrome and other diseases.
77. 1432391 Recipe of Chinese medicine with treating and health care functions
CN
30.07.2003
A61P 31/04 Loading...
A61P 31/04
Loading...
03104977.X
Tianjin Hongri Pharmaceutical Industry Co., Ltd.
Yao Xiaoqing
A61P 31/04
Loading...
The present invention relates to Chinese medicine with treating and health care functions and is especially one Chinese medicine preparation prepared with safflower, red peony root, Chuanxiong rhizome, red sage, angelica and other Chinese medicinal materials. It can antagonize endotoxin and tumor necrosis factor inflammation medium, may be used for preventing and treating pyaemia, multi-organ malfunction syndrome and other diseases.
78. 2528425 一种新型医用卫生栓
CN
01.01.2003
A61F 13/20 Loading...
A61F 13/20
Loading...
01264202.9
天津红日药业股份有限公司
李淑珍
A61F 13/20
Loading...
一种新型医用卫生栓，涉及一种医用品，它属于医用卫生栓。本实用新型提供一种新型医用卫生栓，它具有吸附污物、除臭、抗菌消炎、止痛和加速创面愈合的作用。该种卫生栓结构是医用纱布(3)将纳米银系抗菌粉与活性碳纤维复合构成的抗菌吸附层(2)和活性碳纤维(1)包裹一部分，再将棉线(4)放在被医用纱布包裹部分的中央，然后从医用纱布包裹部分的一端紧压卷成底部有凹槽的圆锥状。主要用于治疗妇科宫颈炎和各类阴道炎与性病，无药源性副作用、无毒、无刺激和无致敏，使用安全。
79. 2512411 纳米活性碳纤维医用敷料
CN
25.09.2002
A61L 15/18 Loading...
A61L 15/18
Loading...
01233195.3
天津红日药业股份有限公司
李淑珍
A61L 15/18
Loading...
一种纳米活性碳纤维医用敷料涉及一种医用品,它属于医用敷料。它由吸附垫、医用纱布和透气性医用无纺布胶带构成。吸附垫为纳米活性碳纤维,吸附垫夹在医用纱布中间,外层医用纱布与透气性医用无纺布胶带粘贴。本实用新型对创面渗出液、分泌物和恶臭具有很强的吸附作用,并具有广谱抗菌消炎、止痛和促进伤口加速愈合的功效,且无毒、无刺激、无致敏、不粘伤口、使用方便。

